Literature DB >> 20517705

Are Cox-2 drugs the second line option in indomethacin responsive headaches?

Jesús Porta-Etessam1, Marialuz Cuadrado, Octavio Rodríguez-Gómez, Sara García-Ptacek, Cristina Valencia.   

Abstract

Paroxysmal hemicrania and hemicrania continua are both indomethacin-responsive headaches. Although indomethacin use to be well tolerated, some patients developed gastrointestinal side effects. We report four cases of hemicrania continua and a patient suffering chronic paroxysmal hemicrania completely responsive to celecoxib. In our experience celecoxib is a good option treatment for patients suffering from hemicrania continua or chronic paroxysmal hemicranea that presents indomethacin adverse effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20517705      PMCID: PMC3452276          DOI: 10.1007/s10194-010-0225-0

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


Introduction

Paroxysmal hemicrania and hemicrania continua are both indomethacin-responsive headaches. Although indomethacin is usually well tolerated, some patients developed gastrointestinal side effects, specially those patients who require long term therapy [1]. Therefore, the use of cyclo-oxygenase-2 specific inhibitors could reduce secondary effects and they are essentially equipotent to indomethacin in vitro and in vivo [2]. Indeed, some reports in the literature indicate the usefulness of the COX-2 inhibitors in the treatment of indomethacin-responsive headaches [3-8]. We report four cases of hemicrania continua and a patient suffering chronic paroxysmal hemicrania completely responsive to COX-2 inhibitors.

Case reports

Case 1

A 42 years-old woman had sudden onset of short-lived pains on the left side of her head. She described the pain periorbital in localisation. She suffers for a month an intense headache with short attacks (about 5−10 min) but high frequency (10−18 attacks per day). The pain associated with lacrimation and nasal congestion, but not pupil changes. Intensity was 8/10 in VAS. Her physical and neurological examinations and a head MRI were absolutely normal. We put her on indomethacin 25 mg 3 times a day, and in 24 h her hemicranial pain completely disappears. Because of legs oedema we discontinued indomethacin and 1 week later the pain returned. We introduced celecoxib 200 mg per day with total recovery. After 12 months of follow up she is still pain free.

Case 2

A 56 years-old man present with an 8 month history of a continuous left-sided headache strictly unilateral. The pain was moderate in intensity but fluctuating (between 2 and 7/10 VAS). The pain exacerbations were associated with lacrimation but not phono, photofobia, nausea or vomiting. An MRI was normal and indomethacin 25 mg 3 times a day was started with completely recovery. Two-month later he started to have gastric symptoms, indomethacin was discontinued and the hemicrania return. With celecoxib 200 mg twice a day the hemicrania disappears. After 10 month the patient is still asymptomatic.

Case 3

A 78 years-old woman with 1 year history of continuous and strictly left-sided headache, fluctuating in intensity (3−9 in VAS) and accompanied by conjuntival injection and nasal congestion during exacerbation time. A cranial MRI was normal. With indomethacin 50 mg 3 times a day the hemicrania disappear, however, she developed disabling subjective tinnitus 1 month later. We discontinued indomethacin and introduced celecoxib 200 mg twice a day with completely recovery that persists 18 month later.

Case 4

A 64 years-old woman with 3 years history of right-sided headache, fluctuating in intensity (2−8 in VAS). She referred rhinorrhea and lacrimation only during headache exacerbation time. A cranial MRI was normal. With indomethacin 25 mg 3 times a day the hemicrania disappear, however, the patient suffer gastrointestinal disturbances. We discontinued indomethacin and introduced celecoxib 200 mg twice a day with completely recovery that persists 10 month later.

Case 5

A 76 years-old man with 6 month history of continuous left-sided headache and facial pain. He scored the pain between 4−9 in VAS. The pain exacerbations were associated with lacrimation. A cranial MRI was normal. With indomethacin 25 mg 3 times a day the hemicrania disappear. After 2 weeks on indometacina he complaint about pyrosis, that persists after omeprazol 40 mg per day. We decided to discontinue indomethacin and introduced celecoxib 200 mg twice a day with completely recovery that persists 6 month later.

Discussion

We present five patients suffering indomethacin-responsive headache case 1 suffering from paroxysmal hemicranias and cases from 2 to 5 from hemicranias continua (Table 1). All of them have absolutely response to indomethacin, but the presence of adverse reactions or intolerability let us discontinued and introduce celecoxib with completely recovery of the symptoms.
Table 1

Clinical characteristics of the patients

CaseAgeGenderHeadache typeSideDoses (mg)Time in month
142FHPLeft20012
256MHCLeft40010
378FHCLeft40018
464FHCRight40010
576MHCLeft4006

All doses correspond to celecoxib

F female, M male, HC hemicrania continua, HP hemicrania paroxistica

Clinical characteristics of the patients All doses correspond to celecoxib F female, M male, HC hemicrania continua, HP hemicrania paroxistica Indomethacin is consider the first-choice drug for the treatment of “indomethacin-responsive headaches”, and the headache resolution is consider as a diagnosis criteria in some of theses headaches. Sometimes patients develop side effects that require us to look for other therapeutic options. Although other drugs have been reported as useful treatment, most of them are anecdotic or single cases [9-15]. Other anti-inflammatory drugs that have been demonstrated as alternative drugs, in particular piroxicam, however, their efficacy is lower when compared with indomethacin [16]. The pathophysiology of theses “indomethacin-response headache” are still unknown, but the cyclo-oxygenase (COX)-2 should be implicated in the pathogenesis. Celecoxib have been previously reported to be effective in the treatment of other indomethacin-responsive headache [3-11], however, there was no absolutely response in all patients [4]. Anyhow, in our experience celecoxib is a good option treatment for patients suffering from hemicrania continua or chronic paroxysmal hemicranea that presents indomethacin adverse effects.
  15 in total

1.  Hemicrania continua responsive to rofecoxib.

Authors:  M F Peres; E Zukerman
Journal:  Cephalalgia       Date:  2000-03       Impact factor: 6.292

2.  Rofecoxib for the treatment of chronic paroxysmal hemicrania.

Authors:  C Lisotto; F Maggioni; F Mainardi; G Zanchin
Journal:  Cephalalgia       Date:  2003-05       Impact factor: 6.292

3.  Episodic paroxysmal hemicrania responsive to calcium channel blockers.

Authors:  F Coria; L E Claveria; F J Jimenez-Jimenez; E V de Seijas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-02       Impact factor: 10.154

4.  Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors.

Authors:  H C Siow
Journal:  Cephalalgia       Date:  2004-05       Impact factor: 6.292

5.  Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua.

Authors:  J A Pareja; A B Caminero; E Franco; J L Casado; J Pascual; M Sánchez del Río
Journal:  Cephalalgia       Date:  2001-11       Impact factor: 6.292

6.  The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Authors:  P Prasit; Z Wang; C Brideau; C C Chan; S Charleson; W Cromlish; D Ethier; J F Evans; A W Ford-Hutchinson; J Y Gauthier; R Gordon; J Guay; M Gresser; S Kargman; B Kennedy; Y Leblanc; S Léger; J Mancini; G P O'Neill; M Ouellet; M D Percival; H Perrier; D Riendeau; I Rodger; R Zamboni
Journal:  Bioorg Med Chem Lett       Date:  1999-07-05       Impact factor: 2.823

7.  Hemicrania continua responds to cyclooxygenase-2 inhibitors.

Authors:  Mario F P Peres; Stephen D Silberstein
Journal:  Headache       Date:  2002-06       Impact factor: 5.887

8.  Chronic paroxysmal hemicrania: orbital phlebography and steroid treatment. A case report.

Authors:  J Hannerz; K Ericson; G Bergstrand
Journal:  Cephalalgia       Date:  1987-09       Impact factor: 6.292

9.  A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua.

Authors:  O Sjaastad; F Antonaci
Journal:  Headache       Date:  1995-10       Impact factor: 5.887

10.  The use of etoricoxib to treat an idiopathic stabbing headache: a case report.

Authors:  Mortimer B O'Connor; Elizabeth Murphy; Mark J Phelan; Michael J Regan
Journal:  J Med Case Rep       Date:  2007-09-21
View more
  9 in total

Review 1.  Hemicrania continua.

Authors:  Robert W Charlson; Matthew S Robbins
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

Review 2.  Paroxysmal hemicrania: an update.

Authors:  Sanjay Prakash; Rushad Patell
Journal:  Curr Pain Headache Rep       Date:  2014-04

Review 3.  When indomethacin fails: additional treatment options for "indomethacin responsive headaches".

Authors:  Shuhan Zhu; Brian McGeeney
Journal:  Curr Pain Headache Rep       Date:  2015-03

Review 4.  Mechanism of action of indomethacin in indomethacin-responsive headaches.

Authors:  Oliver Summ; Stefan Evers
Journal:  Curr Pain Headache Rep       Date:  2013-04

Review 5.  Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.

Authors:  Carlo Baraldi; Lanfranco Pellesi; Simona Guerzoni; Maria Michela Cainazzo; Luigi Alberto Pini
Journal:  J Headache Pain       Date:  2017-07-20       Impact factor: 7.277

6.  Italian guidelines for primary headaches: 2012 revised version.

Authors:  Paola Sarchielli; Franco Granella; Maria Pia Prudenzano; Luigi Alberto Pini; Vincenzo Guidetti; Giorgio Bono; Lorenzo Pinessi; Massimo Alessandri; Fabio Antonaci; Marcello Fanciullacci; Anna Ferrari; Mario Guazzelli; Giuseppe Nappi; Grazia Sances; Giorgio Sandrini; Lidia Savi; Cristina Tassorelli; Giorgio Zanchin
Journal:  J Headache Pain       Date:  2012-05       Impact factor: 7.277

Review 7.  The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias.

Authors:  Alfredo Costa; Fabio Antonaci; Matteo Cotta Ramusino; Giuseppe Nappi
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

Review 8.  Hemicrania continua: clinical review, diagnosis and management.

Authors:  Sanjay Prakash; Payal Patel
Journal:  J Pain Res       Date:  2017-06-29       Impact factor: 3.133

Review 9.  Paroxysmal Hemicrania.

Authors:  Chinar Osman; Anish Bahra
Journal:  Ann Indian Acad Neurol       Date:  2018-04       Impact factor: 1.383

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.